IGF2 LOI (n=13) was associated with a higher risk for loss of MTMR7 in the tumor (OR: 13.71, *p= 0.0157) compared with the control group of CRC cases with neither IGF2 LOI nor T2DM (n=16). This evidence concerns the gene MTMR7 and colorectal carcinoma.